Christopher Codeanne

Christopher Codeanne is a seasoned board member with an advanced degree and extensive domestic and international experience in general business and operations management, financial operations, business analysis, corporate governance, and reporting for publicly traded and venture/private equity-backed organizations. He served on the Board of Directors, was the Audit Committee Chairman, and a member of the Nominating Committee of Cornerstone Therapeutics Inc. (NASDAQ: CRTX) from October 2008 through January 2014. During his tenure, he also served on the Compensation Committee for four years and was part of the Special Committee that facilitated the sale of the business to Chiesi Farmaceutici in January 2014. Most recently, he was the Chief Financial Officer (CFO) of Oxford Performance Materials, where he played a crucial role in the sale of the aerospace assets to Hexcel Corporation. He also served as the Chief Operating Officer (COO) and CFO of Premier Research, significantly improving the company’s operational and financial performance, and was a member of its Board of Directors. At Oncopartners, he was the COO and CFO, overseeing all day-to-day operations including clinical operations, business development, and finance and administration. As the CFO of Averion International Corp., he doubled the company’s size through the financing, acquisition, and integration of a European-based CRO. At SCIREX Corporation LLC, he was a key member of the leadership team that grew the business from under $10MM in revenue to over $150MM. Christopher Codeanne holds an MBA with a concentration in finance from the University of Connecticut and a Bachelor of Science degree in Accounting from Fairfield University. He is also a member of the American Institute of Certified Public Accountants.